D. Mittal

Immunology · 2014

A researcher in the Science corpus: 1 paper; trusts 3 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom D. Mittal trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Dunn
  2. M. Vesely
  3. Robert Schreiber
  4. S. Gasser
  5. Catherine M. Koebel
  6. Lloyd J. Old
  7. S. Topalian
  8. P. Robbins
  9. F. Hodi

Who trusts D. Mittal overall

  1. S. Shalapour
  2. M. Karin
  3. R. Ferris

Papers from D. Mittal's perspective

Ordered by how strongly the researchers D. Mittal trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  3. Natural innate and adaptive immunity to cancer. (Annual Review of Immunology)
  4. An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)
  5. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. (Cancer Research)
  6. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (Nature Medicine)
  7. Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma (Journal of Clinical Oncology)
  8. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor (Nature)
  9. The immunobiology of cancer immunosurveillance and immunoediting. (Immunity)
  10. Adaptive immunity maintains occult cancer in an equilibrium state (Nature)

Their papers